CD133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants

• Published in: British journal of haematology Vol. 169; no. 6; pp. 868 - 878
• Main Authors: Radtke, Stefan, Görgens, André, Kordelas, Lambros, Schmidt, Markus, Kimmig, Klaus R., Köninger, Angela, Horn, Peter A., Giebel, Bernd
• Format: Journal Article
• Language: English
• Published: England 01.06.2015
• Subjects: AC133 Antigen; Antigens, CD - metabolism; Antigens, CD34 - metabolism; bone marrow; Bone Marrow Cells - metabolism; CD133; Colony-Forming Units Assay; cord blood banking; Female; Fetal Blood - chemistry; Glycoproteins - metabolism; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells - metabolism; Humans; Immunophenotyping; Infant, Newborn; Leukocyte Common Antigens - metabolism; Leukocytes, Mononuclear - metabolism; Male; Peptides - metabolism; peripheral blood stem cells; Phenotype; Tissue Donors; umbilical cord blood; umbilical cord blood; cord blood banking; bone marrow; CD133; peripheral blood stem cells
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.13362

Summary The success of haematopoietic stem cell (HSC) transplantation largely depends on numbers of transplanted HSCs, which reside in the CD34+ populations of bone marrow (BM), peripheral blood stem cells (PBSC) and umbilical cord blood (UCB). More specifically HSCs reside in the CD38low/− subpopulation, which cannot be objectively discriminated from mature CD34+ CD38+ progenitors. Thus, better marker combinations for the quantification of more primitive haematopoietic stem and progenitor cells in transplants are required. Recently, by combining CD34 and CD133 we could clearly distinguish CD133+ CD34+ multipotent and lympho‐myeloid from CD133low CD34+ erythro‐myeloid progenitors in UCB samples. To qualify the assessment of CD133 for routine quality control of adult HSC sources, we analysed the developmental potentials of CD133+ and CD133low subpopulations in BM and PBSC. Similar to UCB, CD133 expression objectively discriminated functionally distinct subpopulations in adult HSC sources. By implementing anti‐CD45RA staining, which separates multipotent (CD133+ CD34+ CD45RA−) from lympho‐myeloid (CD133+ CD34+ CD45RA+) progenitor fractions, UCB was found to contain 2–3 times higher multipotent progenitor frequencies than BM and PBSC. To test for the consistency of CD133 expression, we compared CD133+ CD34+ contents of 128 UCB samples with maternal and obstetrical factors and obtained similar correlations to related studies focusing on CD34+ cell contents. In conclusion, implementation of anti‐CD133 staining into existing routine panels will improve the quality control analyses for HSC transplants.